📰 Mark Bleackley News
Page 5 - Mark Bleackley News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Mark Bleackley. Real-time updates on events, politics, business and more.
May 11, 2022
Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL)s Mark Bleackley tells Andrew Scott about a study that investigates the neuro-protective properties of the...
April 28, 2022
Highlights: Positive phase 2a clinical trial results for IHL-42X with 60% of trial participants experiencing at least a 55% reduction in the Apnoea Hypopnea...
March 17, 2022
Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL), one of the first ASX-listed companies to make forays into cannabinoid and psychedelic therapeutic drugs,...
March 17, 2022
Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL)s chief scientific officer Mark Bleackley speaks with Proactive soon after completing preliminary data...
March 17, 2022
Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL)s chief scientific officer Mark Bleackley speaks with Proactive soon after completing preliminary data...
March 17, 2022
Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL), one of the first ASX-listed companies to make forays into cannabinoid and psychedelic therapeutic drugs,...
March 15, 2022
The trial assessed 3 doses of Incannex Healthcare Ltd's cannabinoid combination product IHL-42X at reducing AHI in obstructive sleep apnea.
March 10, 2022
Incannex Healthcare (ASX: IHL) has completed a preliminary analysis of data from a phase 2 proof-of-concept clinical trial investigating novel cannabinoid combination product IHL-42X for the treatment of obstructive sleep apnoea (OSA).
March 10, 2022
/PRNewswire/ -- Highlights: 20% of trial participants experienced a reduction in AHI of greater than 80% (range: 82.7% to 91.5%) during at least one treatment...
March 10, 2022
Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) has wrapped up preliminary analysis of data from its Phase 2 proof-of-concept clinical trial investigating...